top of page
About
Team
Science
News
Careers
Latest News
Press Release
Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors
May 8, 2025
View Press Release
Press Release
Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors
February 24, 2025
View Press Release
Press Release
Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521,
a PARP1 Selective Inhibitor for the Treatment of Solid Tumors
March 11, 2024
View Press Release
Press Release
Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways
January 24, 2024
View Press Release
Article
Exclusive: Reid Huber reunites with former Incyte colleague Wenqing Yao, backs Synnovation with $102M for three trials
Januar
y 24, 2024
View Article
bottom of page